Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Price Target of $46.89

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $46.89.

A number of brokerages have issued reports on TYRA. Piper Sandler reaffirmed an “overweight” rating and set a $56.00 price objective on shares of Tyra Biosciences in a report on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Wedbush restated an “outperform” rating and set a $53.00 target price on shares of Tyra Biosciences in a research report on Thursday, September 10th. Bank of America raised their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, JonesTrading initiated coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price target on the stock.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $21.76 on Friday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -9.07 and a beta of 0.73. The business has a 50-day moving average price of $26.80 and a 200-day moving average price of $31.16. Tyra Biosciences has a twelve month low of $12.58 and a twelve month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Research analysts expect that Tyra Biosciences will post -2.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Tidal Investments LLC bought a new stake in shares of Tyra Biosciences in the second quarter worth about $943,000. WINTON GROUP Ltd bought a new position in Tyra Biosciences during the second quarter valued at approximately $537,000. Engineers Gate Manager LP bought a new position in Tyra Biosciences during the second quarter valued at approximately $1,021,000. Squarepoint Ops LLC grew its holdings in Tyra Biosciences by 211.3% during the 2nd quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock valued at $2,038,000 after buying an additional 43,311 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in Tyra Biosciences during the 2nd quarter valued at approximately $334,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

More Tyra Biosciences News

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Analysts have a consensus price target of $46.89 for Tyra Biosciences (TYRA), indicating substantial upside if the company meets expectations. Tyra Biosciences, Inc. Stock Has Consensus Price Target of $46.89
• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026 and 2027, including FY2026 losses of $2.60 per share versus a prior estimate of $2.86 and FY2027 losses of $2.27 versus $3.20 previously. The firm maintained a Buy rating and a $29 price target. The revised estimates imply expectations for narrower losses, although the company remains unprofitable.
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, producing a 0.0-day short-interest ratio. This unusual figure provides little evidence of meaningful short-selling pressure and may reflect a reporting or data issue.
• Negative Sentiment: Tyra Biosciences shares declined after an analyst downgrade, adding immediate selling pressure and offsetting the more constructive HC Wainwright forecasts. The downgrade’s specific firm, rating change, and rationale were not provided in the available report. Tyra Biosciences Shares Down After Analyst Downgrade

About Tyra Biosciences

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.